RHIZEN

Our journey to be a leading biopharmaceutical company developing differentiated products through cutting-edge science and strategic partnerships started in 2008... Tenalisib- a Phase 2 study in metastatic TNBC patients, post-adjuvant in progress... Proven and seasoned senior leadership team with expertise spanning the entire discovery-development-commercialization value chain

Primary location: Basel Switzerland